From January to July, the cumulative market size of retail pharmacies nationwide reached 299.1 billion yuan, a year-on-year decrease of 3.3%.

As the first domestically approved new oral hypoglycemic compound preparation, the market launch of Dapagliflozin and Metformin Sustained-Release Tablets will further intensify the competition in the domestic hypoglycemic drug market. According to the Zhongkang Kaishi system, overall, the oral hypoglycemic drug retail market tends to stabilize, maintaining sales of over 10 billion yuan for nearly six years. By 2023, the total sales of oral hypoglycemic drugs in domestic tertiary hospitals and retail markets will exceed 30.8 billion yuan. In terms of the retail market, the market size of oral hypoglycemic drugs in 2023 is 12.1 billion yuan, with continuous growth in sales in the first half of this year, reaching nearly 6 billion yuan. In the period from January to July, which are the top 20 varieties among the drugstore sales totaling 299.1 billion? From January to July 2024, the cumulative scale of the national retail pharmacy market reached 299.1 billion yuan, a year-on-year decrease of 3.3%. Focusing on July, the national retail pharmacy market size reversed the downward trend, with a year-on-year increase of 0.7%. Affected by multiple factors such as economic downturn, outpatient integrations, and e-commerce impact, the overall customer traffic level of retail pharmacies has been in a continuous decline since March. However, since the end of June, the resurgence of the COVID-19 pandemic has increased the demand for related medications, leading to a stabilization of customer traffic levels in July, narrowing the gap with the customer traffic levels of the same period last year. 3 batches of 693 centralized procurement varieties are officially implemented Recently, Anhui issued a notice stating that the province will start implementing three centralized procurement projects from September 30, including Guangdong Alliance's essential and emergency rescue drugs, Jiangxi's interferon, and the "3+N" western medicine and traditional Chinese medicine volume-linked procurement in the Beijing-Tianjin-Hebei region. Among them, the Guangdong Alliance procurement cycle will last until December 31, 2026, the Jiangxi Alliance procurement cycle is 4 years, and the Beijing-Tianjin-Hebei "3+N" program is one year. If the three centralized procurement projects involve lower prices, they all require price linkages. After completing the agreement purchase quantity, the Guangdong Alliance will prioritize the purchase of selected products, with the non-selected products using no more than 30% of the total quantity of the same group of products. In addition to the upcoming centralized procurement projects, Anhui will also kick start the traditional Chinese medicine centralized procurement for 2024, led by the Huangshan Medical Insurance Bureau. Huangshan will include 18 product groups comprising 35 traditional Chinese medicine varieties in the centralized procurement, including over-the-counter products such as Cold Capsules, Cold Granules, Fever-Reducing Granules, and Strong Loquat Syrup. With a sales size of over 1.6 billion yuan, Sichuan Kelun Pharmaceutical becomes the third domestic manufacturer On September 18, Sichuan Kelun Pharmaceutical announced that their submission of generic Desogestrel and Ethinylestradiol Tablets was approved and deemed to have passed the consistency evaluation, making them the third domestic enterprise to receive approval for generic Desogestrel and Ethinylestradiol Tablets. According to the databases, the sales of Desogestrel and Ethinylestradiol Tablets in the national inpatient market in 2023 exceeded 1.6 billion yuan. Developed by Abbott Laboratories, Desogestrel and Ethinylestradiol Tablets are a second-tier national medical insurance product. It has been marketed in over 100 countries and is used to treat related diseases caused by insufficient endogenous progesterone, such as dysmenorrhea, endometriosis, threatened miscarriage or habitual abortion caused by progesterone deficiency, and luteal support in assisted reproductive technology. In terms of generic drug layout, several pharmaceutical companies including Zhejiang Gaopan Medical, Zhejiang Aisheng Pharmaceutical, Zhejiang Xianju Pharmaceutical, and Zhejiang Saimu Pharmaceutical have submitted applications for generic Desogestrel and Ethinylestradiol Tablets. Henan initiates "price correction" for products that did not pass evaluation, 67 drugs face being delisted On September 18, the Henan Provincial Public Resource Trading Center issued a notice titled "Notice on Price Correction for Drugs Listed on the Network (First Batch of 2024)", clarifying that drugs with the lowest minimum dosage price higher than the same specification reference drugs, and drugs that did not pass evaluation with the lowest listed price deemed unreasonable, do not comply with the province's network listing rules and need to be subject to price correction. Many of the drugs mentioned by Henan that have prices considered unreasonable are commonly used clinically, including imported drugs such as Novartis' Valsartan Sodium Sacubitril Tablets and Baxter Healthcare's Esmolol Hydrochloride Sodium Chloride Injection. There are also drugs brought in through cooperation, such as Shanghai Fosun Pharmaceutical's Apixaban tablets, and Beihai Kangcheng's Nilotinib Malate tablets. Multiple major pharmaceutical companies question monitoring prices: lower than centralized procurement prices, appeals are of no use On September 18, the Yunnan Provincial Drug Centralized Procurement Platform announced the results of the appeal and questioning of the Yunnan Province's regular network listing work (Batch 20240805): 14 companies appealed, and all the results were not passed, involving well-known companies such as China Resources Sanjiu Medical & Pharmaceutical, Shandong Lukang Pharmaceutical, and Weicai Pharmaceutical. The Drug Supervision Bureau found that of the 14 cases, 9 involved the reasonableness of the national monitoring price for the respective enterprise. For example, China Resources Sanjiu Medical & Pharmaceutical questioned the appropriateness of the monitoring price for Cefuroxime Sodium for Injection that had not passed evaluation. There were even companies challenging the national monitoring prices directly. For example, Beijing Evercare Pharmaceutical stated in the appeal that their Niclosamide Injection did not pass the audit for high than the national monitoring price in the intravenous drug standard listing, and requested an adjustment of the national monitoring price to 4.93 yuan per unit. None of these appeals were successful. However, Yunnan has left a door open for companies: from September 18 to 25, relevant enterprises can consult on the results of the appeal and questioning, and those who still have objections can complain to the Yunnan Provincial Medical Security Bureau. Latest medical equipment centralized procurement launched! Recently, the China Government Procurement Website issued the "Sanya Health Commission - Sanya 2024 Medical Equipment Centralized Procurement Project - Public Bidding Announcement." The document shows that the budget amount for the Sanya 2024 Medical Equipment Centralized Procurement Project is 55.3 million yuan. The project is divided into 4 packages, with Package A having a budget of 5 million yuan, Package B with a budget of 22.6 million yuan, Package C with a budget of 18 million yuan, and Package D with a budget of 9.7 million yuan. english:Je suis dsol, je ne parle pas franais.